Ixico Regulatory News (IXI)

IXICO announces that CEO Derek Hill will be attending the G8 Global CEO Initiative on

Alzheimer's Disease

10 December, 2013 - IXCO plc ("IXICO" or the "Company"), the brain health company, announces that Derek Hill, IXICO's CEO, will attend the G8 Global CEO Initiative on Alzheimer's disease on 12 December, 2013. The CEO Initiative will work with governments, NGOs and other critical stakeholders in the technology, payer, provider and finance industries to achieve the shared goals of preventing and effectively treating Alzheimer's disease by 2025 and enhancing the quality of life of those with the disease and those who care for them.

Specifically, the G8 Global CEO Initiative on Alzheimer's disease aims to:

· Spur innovation and facilitate opportunities to improve the care of those affected by Alzheimer's;

· Reduce the time, cost and risk of drug development to improve the productivity of R&D investments;

· Accelerate a means of prevention and treatment of Alzheimer's, including improving the ability to identify and diagnose the disease;

· Spur new models for care, care preparation and care delivery, and

· Re-shape the environment in which society addresses Alzheimer's patients and caregivers.

Professor Hill is a member of the dementia research champion group, formed in March 2012 by Prime Minister David Cameron to oversee the implementation of the commitments on dementia research in the Dementia Challenge. The group includes some of the country's leading dementia scientists and its work builds on the previous work of the Ministerial Advisory Group on Dementia Research (MAGDR).

For more information visit: http://www.ceoalzheimersinitiative.org

Notes to editors:

IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

Enquiries

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

Ben Atwell

Simon Conway

John Dineen